Virus-like particles
(VLPs) are nanostructures with the
potential
to present heterologous peptides at high density, thereby triggering
heightened immunogenicity. RNA bacteriophage MS2 VLPs are a compelling
delivery platform among them. However, a notable hurdle arises from
the immune response toward MS2 coat protein, swiftly eliminating subsequent
vaccinations via the same vector. Although larger inserts effectively
mask carrier epitopes, current research predominantly focuses on displaying
short conserved peptides (<30 aa). A systematic evaluation regarding
the deterministic ability of MS2 VLPs as a platform for presenting
heterologous peptides remains a gap. In light of this, we employed
the “single-chain dimer” paradigm to scrutinize the
tolerance of MS2 VLPs for peptide/protein insertions. The results
unveiled functional MS2 VLP assembly solely for inserts smaller than
91 aa. Particularly noteworthy is the largest insertion achieved on
the MS2 VLPs to date: the RNA helicase A (RHA) dsRNA-binding domains
(dsRBD1). Attempts to introduce additional linkers or empty coat subunits
fail to augment the expression level or assembly of the MS2 VLPs displaying
dsRBD1, affirming 91 aa as the upper threshold for exogenous protein
presentation. By illuminating the precise confines of MS2 VLPs in
accommodating distinct peptide lengths, our study informs the selection
of appropriate peptide and protein dimensions. This revelation not
only underscores the scope of MS2 VLPs but also establishes a pivotal
reference point, facilitating the strategic manipulation of MS2 VLPs
to design next-generation epitope/antibody-based therapeutics.